ANI PHARMACEUTICALS INC (ANIP)

ANI Pharmaceuticals to Discuss First Quarter 2024 Financial Results on May 10, 2024, at 8:30 a.m. ET

BAUDETTE, Minn., April 18, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company...

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of ANI Pharmaceuticals, Inc. (NASDAQ: ANIP)

/PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) on behalf of the company's shareholders....

ANI Pharmaceuticals Announces the Launch of Baclofen Oral Suspension

BAUDETTE, Minn., April 09, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Baclofen...

ANI Pharmaceuticals Recognizes Sarcoidosis Awareness Month and Patients Living with Sarcoidosis

--ANI Pharmaceuticals is proud to support Sarcoidosis disease awareness--...

ANI Pharmaceuticals to Participate at the Piper Sandler Spring Biopharma Symposium

BAUDETTE, Minn., April 03, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani,...

Noteworthy Monday Option Activity: ANIP, AMC, DOMO

ANI Pharmaceuticals Announces the Launch of Levofloxacin Oral Solution, USP

BAUDETTE, Minn., March 27, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of...

Noteworthy Thursday Option Activity: AI, ANIP, CC

ANI Pharmaceuticals Reports Fourth Quarter and Record Full-Year 2023 Financial Results and Provides 2024 Guidance

Generated quarterly net revenues of $131.7 million, representing year-over-year growth of 39.7%, net income to common shareholders of $0.7 million, GAAP...

Drug Maker Organon Stock Scores Relative Strength Upgrade

In a welcome move, drug maker Organon stock saw its Relative Strength Rating rise from 66 to 71 on Wednesday.

ANI Pharmaceuticals to Present at the Leerink Partners Global Biopharma Conference

BAUDETTE, Minn., Feb. 20, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani,...

ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024, at 8:30 a.m. ET

BAUDETTE, Minn., Feb. 07, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company...

ANI Pharmaceuticals to Participate at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference

BAUDETTE, Minn., Jan. 29, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani,...

Noteworthy Wednesday Option Activity: ANIP, GME, ZS

ANI Pharmaceuticals Announces the Launch of Pentoxifylline Extended-Release Tablets, USP

BAUDETTE, Minn., Jan. 23, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of...

ANI Pharma wins FDA nod for generic Indocin (NASDAQ:ANIP)

ANI Pharmaceuticals (ANIP) has received FDA approval and launched Indomethacin, a generic version of Indocin Oral Suspension. Read more here.

ANI Pharmaceuticals Announces the FDA Approval and Launch of Indomethacin Oral Suspension, USP

BAUDETTE, Minn., Jan. 16, 2024 (GLOBE NEWSWIRE) --  ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received U.S....

Commit To Purchase ANI Pharmaceuticals At $40, Earn 9.9% Annualized Using Options

Notable Two Hundred Day Moving Average Cross - ANIP

ANI Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare Conference

BAUDETTE, Minn., Nov. 22, 2023 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani,...

ANI Pharmaceuticals Non-GAAP EPS of $1.27 beats by $0.43, revenue of $131.83M beats by $19.91M (NASDAQ:ANIP)

ANI Pharmaceuticals beats expectations in Q3 with $1.27 Non-GAAP EPS and $131.8M in revenue.

ANI Pharmaceuticals Reports Record Third Quarter 2023 Financial Results and Raises Full-Year 2023 Guidance

Third Quarter 2023 Financial Results -- Record quarterly net revenues of $131.8 million, representing year-over-year growth of 57.3%; net income available...

ANI Pharmaceuticals to Participate at Two Upcoming Healthcare Conferences

BAUDETTE, Minn., Oct. 30, 2023 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani,...

ANI Pharmaceuticals to Discuss Third Quarter 2023 Financial Results on November 8, 2023, at 8:30 a.m. ET

BAUDETTE, Minn., Oct. 25, 2023 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company...

ANI Pharmaceuticals discloses Head of R&D Shanmugam sells 25K shares (NASDAQ:ANIP)

Head of R&D at ANI Pharmaceuticals, Muthusamy Shanmugam, sold 25K shares indirectly, using a trading plan, totaling 558.5K shares sold in the past three...

ANI Pharmaceuticals' 10% owner sells $1.13M in company shares (NASDAQ:ANIP)

ANI Pharmaceuticals (ANIP) 10% owner and Senior VP-Corporate Development & Strategy, Chad Gassert, sells 20,000 shares at $56.48 each, according to an SEC...

ANI Pharmaceuticals Announces FDA Approval and Commercial Availability of New 1-mL Vial Size of Purified Cortrophin® Gel, Appropriate for Adjunctive Treatment of Certain Patients with Acute Gouty Arthritis Flares

Cortrophin Gel is the only FDA-approved purified corticotropin (ACTH) indicated for the treatment of appropriate patients with acute gouty arthritis flares...

ANI Pharmaceuticals to Present at the Cantor Global Healthcare Conference 2023

BAUDETTE, Minn., Sept. 18, 2023 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani,...

ANI Pharmaceuticals Announces the FDA Approval and Launch of Estradiol Tablets USP

BAUDETTE, Minn., Sept. 12, 2023 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received U.S....

Commit To Buy ANI Pharmaceuticals At $55, Earn 11.4% Annualized Using Options

ANI Pharmaceuticals Announces the FDA Approval and Launch of Estradiol Gel, 0.1%

BAUDETTE, Minn., Aug. 28, 2023 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received U.S....